Available from stock

Celecoxib

SKU: C0439

Category: Lipids, Fatty Acids

Synonyms: 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC 58635, YM 177; 169590-42-5
CAS-Number: C₁₇H₁₄F₃N₃O₂S
Molecular Formula: 381.37
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White to beige powder
Identity: 1H-NMR

Properties

Solvents: Soluble in DMSO (15mg/ml), DMF (25mg/ml) or ethanol (25mg/ml). Insoluble in water.

Shipping: AMBIENT
Short Term Storage: RT
Long Term Storage: +4°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.

Hazard statements: H360D,H373,H410
Precautionary statements: P202 - P260 - P273 - P280 - P308 + P313 - P391
GHS Symbol: GHS08+GHS09
Signal word: Danger
RIDADR: UN3077
Transportation: Packing Group III

Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) and a highly selective cyclooxygenase-2 (COX-2) inhibitor. By preferentially inhibiting COX-2 over COX-1, celecoxib suppresses the formation of pro-inflammatory prostaglandins while minimizing effects on gastric COX-1 activity. It is widely used as a pharmacological tool in inflammation, pain, cancer, and cardiovascular research. In addition to its well-established anti-inflammatory mechanism, celecoxib has been shown to exert COX-2-independent biological effects, including induction of apoptosis, modulation of Bcl-2 family proteins, and regulation of ion channel activity. These properties make celecoxib a widely used research tool in inflammation, oncology, and cell-death signaling studies.
Smiles: Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F
InChi Key: RZEKVGVHFLEQIL-UHFFFAOYSA-N
References: [1] M.M. Goldenberg; Clin. Ther. 21, 1497 (1999) (Review) , [2] N.M. Davies, et al.; Clin. Pharmacokinet. 38, 225 (2000) (Review) , [3] D. Clemett & K.L. Goa; Drugs 59, 957 (2000) (Review) , [4] I.A. Mardini & G.A. Fitzgerald; Mol. Interv. 1, 30 (2001) , [5] A.T. Koki & J.L. Masferrer; Cancer Control 9, 28 (2002) (Review) , [6] V. Jendrossek, et al.; FASEB J. 17, 1547 (2003) , [7] K. Kismet, et al.; Cancer Detect. Prev. 28, 127 (2004) (Review) , [8] D. Jiang, et al.;Int. J. Mol. Sci. 11, 4106 (2010) , [9] K. Antoniou, et al.; Expert Opin. Pharmacother. 8, 1719 (2007) (Review) , [10] L.L. Winfield & F. Payton-Stewart; Future Med. Chem. 4, 361 (2012) (Review) , [11] V. Jendrossek; Cancer Lett. 332, 313 (2013) (Review) , [12] R.V. Frolov & S. Singh; Eur. J. Pharmacol. 730, 61 (2014) (Review) , [13] A.F. Khafaga, et al.; Nanomedicine 16, 1691 (2021) (Review)

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) and a highly selective cyclooxygenase-2 (COX-2) inhibitor. By preferentially inhibiting COX-2 over COX-1, celecoxib suppresses the formation of pro-inflammatory prostaglandins while minimizing effects on gastric COX-1 activity. It is widely used as a pharmacological tool in inflammation, pain, cancer, and cardiovascular research. In addition to its well-established anti-inflammatory mechanism, celecoxib has been shown to exert COX-2-independent biological effects, including induction of apoptosis, modulation of Bcl-2 family proteins, and regulation of ion channel activity. These properties make celecoxib a widely used research tool in inflammation, oncology, and cell-death signaling studies.

SKU: C0439 Category: Lipids, Fatty Acids

Additional information

Additional information

Synonyms	4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC 58635, YM 177
Purity	≥98% (HPLC)
Appearance	White to beige powder
CAS-Number	169590-42-5
Molecular Formula	C17H14F3N3O2S
Molecular Weight	381.37
Identity	1H-NMR
Solvents	Soluble in DMSO (15mg/ml), DMF (25mg/ml) or ethanol (25mg/ml). Insoluble in water.
Smiles	Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F
InChi Key	RZEKVGVHFLEQIL-UHFFFAOYSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H360D,H373,H410
Precautionary statements	P202 – P260 – P273 – P280 – P308 + P313 – P391
GHS Symbol	GHS08+GHS09
Signal word	Danger
RIDADR	UN3077
Transportation	Packing Group III
References	[1] M.M. Goldenberg; Clin. Ther. 21, 1497 (1999) (Review), [2] N.M. Davies, et al.; Clin. Pharmacokinet. 38, 225 (2000) (Review), [3] D. Clemett & K.L. Goa; Drugs 59, 957 (2000) (Review), [4] I.A. Mardini & G.A. Fitzgerald; Mol. Interv. 1, 30 (2001), [5] A.T. Koki & J.L. Masferrer; Cancer Control 9, 28 (2002) (Review), [6] V. Jendrossek, et al.; FASEB J. 17, 1547 (2003), [7] K. Kismet, et al.; Cancer Detect. Prev. 28, 127 (2004) (Review), [8] D. Jiang, et al.;Int. J. Mol. Sci. 11, 4106 (2010), [9] K. Antoniou, et al.; Expert Opin. Pharmacother. 8, 1719 (2007) (Review), [10] L.L. Winfield & F. Payton-Stewart; Future Med. Chem. 4, 361 (2012) (Review), [11] V. Jendrossek; Cancer Lett. 332, 313 (2013) (Review), [12] R.V. Frolov & S. Singh; Eur. J. Pharmacol. 730, 61 (2014) (Review), [13] A.F. Khafaga, et al.; Nanomedicine 16, 1691 (2021) (Review)
Quantity	10 mg, 50 mg, 1 g, Bulk